Pasi Jänne, MD, PhD, Dana-Farber/Harvard Cancer Center, Boston, MA, discusses an investigation into the biology of EGFR resistance mutations in non-small cell lung cancer (NSCLC), including C797S, using a clinico-genomic database. Since the widespread introduction of osimertinib as standard of care therapy for EGFR-mutant NSCLC, understanding and overcoming resistance mechanisms has been widely studied. From 228 samples, the study identified 261 osimertinib resistance mutations in EGFR, of which 66% were C797S. T790M co-occurred in 76% of C797S mutant samples and its prevalence decreased over time. Prof. Jänne explains the importance of these genomic analyses as new agents enter the clinic that aim to overcome these resistance mutations. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

свернуть